Drug Interaction study between AZD3480 and warfarin - DDI
Study identifier:D3690C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A single-centre, double blind, randomized, two-way cross-over study of repeated doses of AZD3480 and single dose of warfarin to evaluate the pharmacokinetic interaction of AZD3480 and warfarin and the effect of AZD3480 pharmacodynamic in healthy male subjects (phase I
Medical condition
Alzheimer's disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3480, Placebo, Warfarin
Sex
Male
Actual Enrollment
26
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Sept 2007
Primary Completion Date: 01 Feb 2009
Study Completion Date: 01 Feb 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD3480 + warfarin | Drug: AZD3480 AZD3480 capsules qd, 12 days Drug: Warfarin Warfarin: single dose on day 6 |
| Experimental: 2 Placebo+ warfarin | Drug: Placebo Placebo capsules qd, 12 days Drug: Warfarin Warfarin: single dose on day 6 |
Contacts
Investigators
Principal Investigator
Hans-Göran Hårdemark
Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden
